BCC Research Predicts Ovarian Cancer Diagnostics And Therapies Market To Reach $34.6 Billion In 2018
Wellesley, MA (PRWEB) July 24, 2013 -- In the new report, THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER (Report Code: HLC143A), from BCC Research (http://www.bccresearch.com), the therapies and diagnostics market for ovarian cancer was valued at $16 billion in 2012 and is expected to reach $18.7 billion in 2013. The report forecasts total market value to reach $34.6 billion in 2018, after increasing at a five-year compound annual growth rate (CAGR) of 13.1%.
This BCC Research report is focused on the surgery, trans-vaginal ultrasound, imaging test, blood test, chemotherapy, and novel therapy markets. Each of these markets is forecasted year on year in the report. The ovarian cancer diagnostics and therapies market is a highly competitive landscape with a number of emerging players possessing a strong product pipeline.
Ovarian cancer has few early warning symptoms, a lack of effective diagnostic capabilities, and a highly aggressive nature. Owing to these unique features, the disease has been the subject of heavy research and development and has caught the interest of pharmaceutical and medical industries. According to BCC Research, the average five-year survival rate after diagnosis is only 45%, illustrating the need for more effective treatment and better diagnostic tools.
According to BCC Research, the disease has a high mortality rate due to lack of early detection and diagnosis. BCC Research discusses the most promising new diagnostic therapies under development in this report, and explains how these new therapies will affect market valuations over the next five years.
There are three types of ovarian cancer tumors: epithelial, germ cell, and stromal. The most common type of tumor is epithelial, comprising nearly 90% of all tumors found in ovarian cancer. This BCC Research report explores the differences in treatment protocols by tumor type, and also provides information on metastasis.
BCC Research’s report describes how there are no known causes for ovarian cancer to date, although certain risk factors do exist. Some of these factors include family history, age, and inherited mutations in the genes called BRCA1 and BRCA2. There are a number of other risk factors currently under research. BCC Research explores these factors in depth through this study, weighing scientific data and literature behind each factor.
Ovarian cancer is a global disease that can be found throughout the developing and industrialized world. This BCC Research report describes how emerging markets will begin increasing their share of expenditures on therapies and diagnostics, while, developed markets will begin to decrease their use of branded drugs in response to cost containment measures.
This study will be of interest largely to the pharmaceutical and biotechnology industries, but will also benefit clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the concerned sector.
Steven Cumming, BCC Research, http://www.bccresearch.com, 781-489-7301 632, [email protected]
Share this article